Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development
- 280 Downloads
Purpose of Review
The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition.
Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing.
The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.
KeywordsTie2 inhibition Angiopoietin inhibition Angiogenesis Anti-angiogenic therapy
Compliance with Ethical Standards
Conflict of Interest
Jessica Gillen declares that she has no conflict of interest.
Debra Richardson has received compensation from Genentech and Ipsen for participation on advisory boards, and has served on steering committees for and received travel grants from Tesaro and Karyopharm Therapeutics.
Kathleen Moore has received research funding for investigator-initiated trials from ImmunoGen, Genentech/Roche, PTC Therapeutics, and Eli Lilly; has received compensation for participation on advisory boards from Clovis, AstraZeneca, Tesaro, ImmunoGen, Genentech/Roche, VBL Therapeutics, Janssen, Aravive, OncoMed, Samumed, and Merck; has received compensation for sales force training from Pfizer; and served as an unbranded speaker for AstraZeneca for DNA damage response.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 5.Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, et al. The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2(hi) macrophages in breast cancer and pancreatic neuroendocrine tumors. Mol Cancer Ther. 2017;16(11):2486–501.PubMedPubMedCentralCrossRefGoogle Scholar
- 26.Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, et al. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014;135(1):25–33.PubMedCrossRefGoogle Scholar
- 29.• Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol. 2016;27(Suppl 1):i33–9 This article reviewed the current state of anti-angiogenic therapies as used in ovarian cancers and helped clarify the role of anti-VEGF and anti-angiopoietin therapy specifically. PubMedPubMedCentralCrossRefGoogle Scholar
- 30.• Monk BJ, et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016;143(1):27–34 This was the first phase 3 trial of a Tie2/angiopoietin-2 inhibitor in ovarian cancer. It specifically evaluated both progression-free and overall survival in women with recurrent disease. PubMedCrossRefGoogle Scholar
- 31.Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, et al. ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017;70:111–21.PubMedCrossRefGoogle Scholar
- 33.• Moore KN, et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: an NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015;138(3):513–8 This study determined that further investigation into trebananib in women with recurrent or persistent endometrial cancer was not warranted. PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Peeters M, Strickland AH, Lichinitser M, Suresh AVS, Manikhas G, Shapiro J, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer. 2013;108(3):503–11.PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol. 2013;24(3):710–8.PubMedCrossRefGoogle Scholar
- 37.• Dieras V, et al. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: a phase 2 randomized study. Breast. 2015;24(3):182–90 This article is one of the primary studies evaluating trebananib in the frontline setting for breast cancer. No significant improvements were noted in PFS at the given dosese, but noted rationale for investigation of increased doses. PubMedCrossRefGoogle Scholar
- 38.Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, et al. Phase 1b study of trebananib plus paclitaxel and trastuzumab in patients with HER2-positive locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2018.Google Scholar
- 42.Jesus Del Santo Anampa Mesias MHO, Xue X, Condeelis J, Sparano JA. Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer (MBC). Chicago: American Association of Cancer Research Annual Meeting; 2018.Google Scholar
- 45.Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, et al. Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors. Clin Cancer Res. 2018;24(12):2749–57.PubMedCrossRefGoogle Scholar